Philina Lee
Director/Board Member chez FUSN PHAR
Fortune : 3 M $ au 31/03/2024
Postes actifs de Philina Lee
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| FUSN PHAR | Director/Board Member | 11/02/2021 | - |
| Independent Dir/Board Member | 11/02/2021 | - | |
| BLUEPRINT MEDICINES CORPORATION | Corporate Officer/Principal | 01/01/2021 | - |
Historique de carrière de Philina Lee
Anciens postes connus de Philina Lee
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ALGETA ASA | Corporate Officer/Principal | - | - |
Formation de Philina Lee
| Massachusetts Institute of Technology | Doctorate Degree |
| University of Alberta | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 3 |
| Canada | 3 |
| Norvège | 2 |
Opérationnelle
| Corporate Officer/Principal | 2 |
| Undergraduate Degree | 1 |
| Director/Board Member | 1 |
Sectorielle
| Health Technology | 4 |
| Finance | 2 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BLUEPRINT MEDICINES CORPORATION | Health Technology |
| FUSN PHAR | Health Technology |
| Entreprise privées | 1 |
|---|---|
Algeta ASA
 Algeta ASA Pharmaceuticals: MajorHealth Technology Algeta ASA is engaged in the development of products for the treatment of cancer. The company focuses on the development of anti-cancer drugs, and its research and development of compounds focuses on the various applications of a few base compounds. Its products, Alpharadin and Thorium-227, are being developed for treatment of skeletal metastases originating from prostate and breast cancer. The company was founded by Roy H. Larsen and Øyvind Sverre Bruland in 1997 and is headquartered in Oslo, Norway. | Health Technology |
- Bourse
- Insiders
- Philina Lee
- Expérience
